摘要
目的:探讨FLAG方案治疗复发或难治性急性髓系白血病患者的疗效。方法:采用FLAG方案治疗复发或难治性急性髓系白血病患者37例。FLAG方案为氟达拉滨(Flu)30 mg/m2,dl~d5,阿糖胞苷(Ara-C)2 g,d1~d5,粒细胞集落刺激因子(G-CSF)5μg/kg d0直到白细胞恢复超过>1.5×109/L。结果:37例患者中12例完全缓解(CR),CR率为32.4%。随访中位总生存期(overall survival,OS)为6.2个月,中位无进展生存期(progression-freesurvival,PFS)为10.3个月。26例复发患者FLAG方案治疗前少于3个疗程化疗的患者与3个及3个以上化疗疗程的患者疗效比较,差异有统计学意义(P<0.01)。结论:FLAG方案治疗复发、难治的急性髓系白血病患者效果良好。
Objective: To study the effect of FLAG program on relapsed or refractory acute myeloid leukemia.Methods:A total of 37 patients with relapsed or refractory acute myeloid leukemia were treated with FLAG program: fludarabine 30 mg/m2,dl-d5,Ara-C 2 g,d1-d5,granulocyte colony stimulating factor(G-CSF) 5 μg/kg d0 until the white blood cell recovery above 1.5 × 109 / L.Results: 12 cases had complete remission(CR),CR rate was 32.4%.The median overall survival(OS) was 6.2 months,median progress free survival(PFS) was 10.3 months.There was significant difference between recurrence patients with pre-FLAG treatment of less than 3 cycles of chemotherapy and patients with three or more cycles of chemotherapy(P0.01) in 26 cases.Conclusions: FLAG program is a better choice for relapse or refractory patients with acute myelogenous leukemia.
出处
《海南医学院学报》
CAS
2010年第6期729-731,共3页
Journal of Hainan Medical University
基金
海南医学院科研基金资助学报项目(0020100202)~~
关键词
急性髓系白血病
复发
难治
氟达拉滨
Acute myeloid leukemia
Relapse
Refractory
Fludarabine